^
Association details:
| Biomarker: | TNFRSF17 deletion |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | Abecma (idecabtagene vicleucel) (BCMA-targeted CAR-T immunotherapy) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
Published date:
02/08/2021
Excerpt:
In this work, by performing single-cell transcriptome profiling on serially collected bone marrow (BM) samples, we show biallelic loss of BCMA as one of the resistance mechanisms to anti-BCMA CAR T-cell therapy with Idecabtagene Vicleucel in a patient with initial response but relapse with resistance to retreatment with the same CAR T-cell product.
DOI:
https://doi.org/10.7910/DVN/1RKYQ8
